Search PubMedSearch

PubMed · 9198205

The factor VIIa/tissue factor complex.

Abstract

The tissue factor:factor VIIa (TF:F.VIIa) complex is the physiological initiator of blood coagulation and plays a role both in normal hemostasis and in various thrombotic disorders. The TF:F.VIIa crystal structure presented here shows the two molecules in association as a complex and provides a ready structural explantation for most of the complementary observations on the complex obtained by other techniques. This is only one F.VII structure of a series along the activation pathway going from zymogen F.VII, through F.VIIa alone, towards that in the ternary complex with a macromolecular substrate such as F.IX or F.X. To fully understand the activation of F.VIIa by TF will require further structural work, but in the meantime this structure may be used in the search for more effective and more specific anticoagulants.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D W Banner. 1997. The factor VIIa/tissue factor complex.. https://pubmed.ncbi.nlm.nih.gov/9198205/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Proteolytic activation of purified human procarboxypeptidase U.

Carboxypeptidase U (CPU, EC 3.4.17.20) is a recently described basic carboxypeptidase which circulates in plasma as an enzymatically inactive precursor procarboxypeptidase U (proCPU), also known as plasma carboxypeptidase B precursor or thrombin activatable fibrinolysis inhibitor (TAFI). The activation of the zymogen proceeds through a proteolytic cleavage at Arg-92. The active form - CPU - is able to retard the initial phase of fibrinolysis by cleaving C-terminal lysine residues exposed on fibrin partially degraded by the action of plasmin. These C-terminal lysine residues are essential for the high affinity binding of plasminogen to fibrin and the subsequent activation to plasmin. In this report, the activation of purified human proCPU was studied using trypsin and some key proteases of the coagulation and fibrinolytic cascade, i.e., kallikrein, plasmin and thrombin. The most efficient activation is obtained in the presence of thrombin in complex with thrombomodulin. After in vitro activation, CPU is unstable at 37 degrees C (T(1/2)=15 min). Its stability can be improved dramatically using lower temperatures.

Blood Coagulation

Preparation and characterization of 'heparinocytes': erythrocytes with covalently bound low molecular weight heparin.

In an attempt to create the possibility of stable, long acting, intravascular anticoagulation, low molecular weight heparin was modified by introducing a sulfhydryl group into the molecule (LMWH-SH). Human erythrocytes were covalently grafted with LMWH-SH by the use of a heterobifunctional coupling reagent which reacts with the SH group of LMWH-SH and surface exposed amino groups of erythrocytes now called 'heparinocytes' (HC). HC were morphologically indistinguishable from untreated erythrocytes and displayed identical osmotic resistance. The functionality of HC was analyzed by classical coagulation tests in which they dose dependently inhibited clot formation. HC were also functional in recalcified whole blood inhibiting thrombin formation as assessed by the cleavage of the chromogenic substrate S-2238. The system appears applicable as a potential autologous, long-term anticoagulant treatment or prophylaxis.

Blood Coagulation

The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation.

Thrombin is central to the process of coagulation and monitoring its activity is a reliable indicator of the rate and extent of coagulation. I have employed a range of fluorogenic peptide substrates as indicators of coagulation via the formation of active thrombin. This system enabled coagulation to be monitored in a kinetic fashion, and the use of fluorescence enabled a wide range of samples to be analyzed including lyophilized plasma containing fibrin, fresh platelet-poor plasma, platelet-rich plasma, and even whole blood. Coagulation could be monitored following triggering by tissue factor, ellagic acid, or each of the proteases preceding thrombin in the coagulation network. Using this assay procedure I have investigated the anticoagulant activities of a number of compounds and the results indicate that this assay would be useful for the kinetic analysis of coagulation in various plasma preparations, or even whole blood.

Blood Coagulation